as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹5,274.0
Change
-52.0 (-0.98%)
Open
₹5,322.5
Prev. Close
₹5,326.0
Day High
₹5,325.0
Day Low
₹5,237.0
Volume Analysis
Traded
28,742
Delivered
11,676
Delivery %
40.62%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (20.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (32.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹5,408.34 | ₹5,366.67 | ₹5,320.34 | ₹5,278.67 | ₹5,232.34 | ₹5,190.67 | ₹5,144.34 |
| Fibonacci | ₹5,366.67 | ₹5,333.05 | ₹5,312.29 | ₹5,278.67 | ₹5,245.05 | ₹5,224.29 | ₹5,190.67 |
| Camarilla | ₹5,298.2 | ₹5,290.13 | ₹5,282.07 | ₹5,278.67 | ₹5,265.93 | ₹5,257.87 | ₹5,249.8 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-3.47%
1 Week
-1.68%
1 Month
-1.51%
3 Months
-5.31%
6 Months
+0.56%
1 Year
-2.93%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹2,237.67
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
15.66%
Net margin 14.61% × asset turnover 0.71x × equity multiplier 1.51x
Company Overview
Sector
Healthcare
Market Cap
₹63,680 Cr
P/E (TTM)
28.0
ROE
18.9%
Book Value
₹1,156.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Alkem Laboratories Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Momentum (31/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%); promoter holding is falling. Strong 3-year EPS growth (32.7%).
TopFund Score — Fundamentals Quality
69/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has been maintaining a healthy dividend payout of 26.3%
- −Promoter holding has decreased over last quarter: -1.50%
- −The company has delivered a poor sales growth of 10.7% over past five years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Nitin Agrawal resigned as CFO on 30 July 2026; cessation effective 30 September 2026.
Alkem Laboratories to meet HDFC Mutual Fund in Mumbai on 7 October 2026.
Alkem issued Euro 54.45 million corporate guarantee for Occlutech Holding AG's Euro 49.5 million loan.
Alkem launches NeuCeno (cenobamate) in India for partial-onset seizures in adults.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,968 | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Expenses + | 2,579 | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 | 2,974 |
| Operating Profit | 389 | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 | 766 |
| OPM % | 13.0% | 22.0% | 21.0% | 14.0% | 20.0% | 22.0% | 23.0% | 12.0% | 22.0% | 23.0% | 22.0% | 14.0% | 20.0% |
| Other Income + | 66 | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 | 153 |
| Interest | 30 | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 | 47 |
| Depreciation | 72 | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 | 100 |
| Profit before tax | 353 | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 | 772 |
| Tax % | 18.0% | 5.0% | 8.0% | 17.0% | 11.0% | 10.0% | 12.0% | 18.0% | 13.0% | 13.0% | 16.0% | 40.0% | 32.0% |
| Net Profit + | 288 | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| EPS in Rs | 24 | 52 | 50 | 25 | 46 | 58 | 52 | 26 | 56 | 64 | 53 | 20 | 43 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,674 | 4,905 | 5,688 | 6,401 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 | 15,081 |
| Expenses + | 3,248 | 4,038 | 4,687 | 5,392 | 6,237 | 6,868 | 6,920 | 8,580 | 9,977 | 10,419 | 10,452 | 11,706 | 12,049 |
| Operating Profit | 427 | 866 | 1,001 | 1,009 | 1,120 | 1,476 | 1,945 | 2,054 | 1,622 | 2,249 | 2,512 | 3,007 | 3,032 |
| OPM % | 12.0% | 18.0% | 18.0% | 16.0% | 15.0% | 18.0% | 22.0% | 19.0% | 14.0% | 18.0% | 19.0% | 20.0% | 20.0% |
| Other Income + | 176 | 227 | 110 | 115 | 82 | 102 | 230 | 146 | 101 | 186 | 494 | 407 | 412 |
| Interest | 81 | 71 | 45 | 55 | 55 | 65 | 59 | 52 | 107 | 112 | 122 | 161 | 178 |
| Depreciation | 71 | 93 | 101 | 143 | 193 | 253 | 275 | 304 | 310 | 299 | 357 | 382 | 395 |
| Profit before tax | 451 | 928 | 965 | 926 | 955 | 1,260 | 1,842 | 1,844 | 1,305 | 2,023 | 2,527 | 2,871 | 2,872 |
| Tax % | 13.0% | 19.0% | 6.0% | 31.0% | 19.0% | 9.0% | 12.0% | 9.0% | 23.0% | 10.0% | 12.0% | 18.0% | — |
| Net Profit + | 392 | 752 | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 | 2,204 |
| EPS in Rs | 33 | 62 | 75 | 53 | 64 | 94 | 133 | 138 | 82 | 150 | 181 | 193 | 180 |
| Dividend Payout % | 12.0% | 20.0% | 20.0% | 25.0% | 25.0% | 27.0% | 23.0% | 25.0% | 61.0% | 27.0% | 25.0% | 28.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 2,975 | 3,668 | 4,444 | 4,840 | 5,415 | 6,137 | 7,353 | 8,614 | 9,021 | 10,288 | 11,961 | 13,796 |
| Borrowings + | 1,306 | 658 | 659 | 998 | 944 | 1,616 | 1,707 | 2,668 | 1,397 | 1,418 | 1,381 | 2,047 |
| Other Liabilities + | 986 | 1,184 | 1,440 | 1,803 | 1,824 | 2,169 | 2,435 | 2,763 | 3,315 | 3,844 | 4,325 | 4,991 |
| Total Liabilities | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,858 |
| Fixed Assets + | 1,374 | 1,450 | 1,797 | 2,284 | 2,530 | 2,908 | 2,793 | 2,902 | 2,683 | 2,873 | 2,852 | 3,871 |
| CWIP | 111 | 172 | 299 | 381 | 493 | 363 | 393 | 339 | 323 | 159 | 548 | 282 |
| Investments | 481 | 509 | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 484 | 1,846 | 1,869 |
| Other Assets + | 3,325 | 3,403 | 3,918 | 4,555 | 4,861 | 6,413 | 8,000 | 10,457 | 10,129 | 12,060 | 12,445 | 14,836 |
| Total Assets | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,858 |
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 325 | 726 | 471 | 266 | 780 | 585 | 1,265 | 1,111 | 1,682 | 1,948 | 1,913 | 1,963 |
| Cash from Investing Activity + | -235 | 205 | -294 | -351 | -318 | -737 | -995 | -1,433 | 120 | -1,011 | -1,288 | -1,682 |
| Cash from Financing Activity + | -52 | -927 | -138 | 85 | -379 | 79 | -272 | 380 | -1,761 | -1,145 | -811 | -503 |
| Net Cash Flow | 39 | 3 | 40 | 0 | 82 | -73 | -2 | 58 | 42 | -207 | -186 | -222 |
| CFO/OP | 101 | 107 | 73 | 47 | 92 | 59 | 86 | 73 | 121 | 105 | 96 | 86 |
| Free Cash Flow | 190 | 472 | -163 | -411 | 253 | 237 | 1,116 | 783 | 1,453 | 1,761 | 1,278 | 1,476 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 19.58% | 18.86% | 18.51% | 16.37% | 16.12% | 16.19% | 16.05% | 16.05% | 17.39% | 17.3% | 17.25% | 17.25% |
| Promoters | 56.74% | 56.74% | 56.74% | 56.38% | 55.66% | 55.66% | 55.13% | 53.04% | 51.2% | 51.2% | 51.2% | 49.7% |
| FII | 6.03% | 8.49% | 9.11% | 8.69% | 9.02% | 10.14% | 9.4% | 9.11% | 9.47% | 9.97% | 10.15% | 10.42% |
| DII | 17.63% | 15.91% | 15.63% | 18.56% | 19.21% | 18.01% | 19.42% | 21.8% | 21.93% | 21.54% | 21.39% | 22.64% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Alkem Laboratories Ltd. (this stock) | 63,680 | 28.0 | 4.61 | 18.9% |
| Biocon Limited. | 61,298 | 84.3 | 1.79 | 1.4% |
| Aster Dm Quality Care Ltd | 66,312 | 184.0 | 9.38 | 11.3% |
| Fortis Healthcare Ltd | 66,565 | 62.4 | 6.71 | 11.2% |
| Glenmark Pharmaceuticals | 69,000 | 22.1 | 6.56 | 23.6% |
| Ipca Laboratories Ltd | 50,650 | 36.9 | 6.28 | 15.7% |
| Anthem Biosciences Ltd | 49,633 | 83.6 | 16.25 | 22.3% |
Which Mutual Funds Hold Alkem Laboratories Ltd.?
Frequently Asked Questions about Alkem Laboratories Ltd.
Alkem Laboratories Ltd. (ALKEM) closed at ₹5,274.0 on NSE on 25 September 2026, down 52.0 (0.98%) from the previous close.
Alkem Laboratories Ltd. trades on the NSE (National Stock Exchange of India) under the symbol ALKEM.
Alkem Laboratories Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 28.0.
Alkem Laboratories Ltd. has a dividend yield of 1.0%.
Alkem Laboratories Ltd.'s 52-week high is ₹5,934.0 and its 52-week low is ₹5,051.0.
Alkem Laboratories Ltd. has a market capitalisation of ₹63,680 crore.
Alkem Laboratories Ltd. has a TopFund Quality Score of 69/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Alkem Laboratories Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.